Potential role of p21 Activated Kinase 1 (PAK1) in the invasion and motility of oral cancer cells. by Parvathy, Muraleedharan et al.
Himmelfarb Health Sciences Library, The George Washington University
Health Sciences Research Commons
Biochemistry and Molecular Medicine Faculty
Publications Biochemistry and Molecular Medicine
2016
Potential role of p21 Activated Kinase 1 (PAK1) in
the invasion and motility of oral cancer cells.
Muraleedharan Parvathy
Sreeharshan Sreeja
Rakesh Kumar
George Washington University
M. Radhakrishna Pillai
Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/smhs_biochem_facpubs
Part of the Cell and Developmental Biology Commons, and the Molecular Biology Commons
This Journal Article is brought to you for free and open access by the Biochemistry and Molecular Medicine at Health Sciences Research Commons. It
has been accepted for inclusion in Biochemistry and Molecular Medicine Faculty Publications by an authorized administrator of Health Sciences
Research Commons. For more information, please contact hsrc@gwu.edu.
APA Citation
Parvathy, M., Sreeja, S., Kumar, R., & Pillai, M. R. (2016). Potential role of p21 Activated Kinase 1 (PAK1) in the invasion and motility
of oral cancer cells.. BMC Cancer, 16 (suppl.1). http://dx.doi.org/10.1186/s12885-016-2263-8
RESEARCH Open Access
Potential role of p21 Activated Kinase 1
(PAK1) in the invasion and motility of oral
cancer cells
Muraleedharan Parvathy1†, Sreeharshan Sreeja1†, Rakesh Kumar1,2 and Madhavan Radhakrishna Pillai1*
From Indian Genetics Congress 2015
Kattankulathur, India. 4–6 March 2015
Abstract
Background: Oral cancer malignancy consists of uncontrolled division of cells primarily in and around the floor of
the oral cavity, gingiva, oropharynx, lower lip and base of the tongue. According to GLOBOCAN 2012 report, oral
cancer is one of the most common cancers among males and females in India. Even though significant
advancements have been made in the field of oral cancer treatment modalities, the overall prognosis for the
patients has not improved in the past few decades and hence, this demands a new thrust for the identification of
novel therapeutic targets in oral cancer. p21 Activated Kinases (PAKs) are potential therapeutic targets that are
involved in numerous physiological functions. PAKs are serine-threonine kinases and they serve as important
regulators of cytoskeletal dynamics and cell motility, transcription through MAP kinase cascades, death and survival
signalling, and cell-cycle progression. Although PAKs are known to play crucial roles in cancer progression, the role
and clinical significance of PAKs in oral cancer remains poorly understood.
Results: Our results suggest that PAK1 is over-expressed in oral cancer cell lines. Stimulation of Oral Squamous Cell
Carcinoma (OSCC) cells with serum growth factors leads to PAK1 re-localization and might cause a profound
cytoskeletal remodelling. PAK1 was also found to be involved in the invasion, migration and cytoskeletal
remodelling of OSCC cells.
Conclusions: Our study revealed that PAK1 may play a crucial role in the progression of OSCC. Studying the role of
PAK1 and its substrates is likely to enhance our understanding of oral carcinogenesis and potential therapeutic
value of PAKs in oral cancer.
Keywords: p21 Activated Kinase, Oral cancer, Invasion, Cytoskeletal remodelling, Migration
Background
According to GLOBOCAN 2012 [1], there has been 14.1
million new cancer cases, 8.2 million cancer deaths and
32.6 million people living with cancer worldwide within
5 years of diagnosis. Carcinoma of lip and oral cavity is
one of the most frequent causes of cancer deaths among
males. Ninety percent of oral cancers are OSCC [2],
originating from the flat cells (called squamous cells)
that cover the surface of the oral cavity and oropharynx.
With the advent of modern techniques, our understand-
ing about the pathogenesis of oral cancer has increased
over a period of time. But despite this, oral cancer has one
of the lowest survival rates- 50 percent, within a five-year
period (http://www.oralcancerfoundation.org/facts/). This
calls for the identification of new therapeutic targets
and one such potential set of target molecules are
p21 Activated Kinases (PAKs).
PAKs were one of the first classes of Rho-GTPases-
regulated kinases [3] to be identified. PAKs are a family
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of evolutionarily conserved group of serine-threonine
kinases. So far, six PAK family members have been iden-
tified in mammals [4] and they have been classified into
two sub-groups- Group I PAKs (PAKs 1-3) and Group II
PAKs (PAKs 4-6). While Group I PAKs are activated by
a variety of GTPase -dependent and -independent mech-
anisms, Group II PAKs are constitutively activated. PAKs
are considered prime regulators of the actin cytoskeleton
and motility [5]. Due to their central role in actin re-
modelling and their ability to activate Matrix metallo-
proteinases (MMPs), Rho GTPases play an important
role in tumor cell invasion and metastasis [6]. The
current evidence suggests the involvement of PAKs in
motility [7–10], cell survival [11, 12], anchorage-
independent growth [13], angiogenesis [14–18], inva-
sion [18, 19], migration [20, 21] and regulation of cell
cycle and mitosis [22, 23]. Consequently, PAKs have
also been implicated in a number of pathological con-
ditions including cancer [24].
Our interest resides in the PAK1 kinase, a member of
group I PAKs. The roles of PAK1 in breast [25–30],
colon [31–33], lung [34, 35], melanoma [36], prostate
[37, 38], ovarian cancers [39] are well studied. Even
though PAKs are known to play roles in the crucial steps
of cancer progression, its role and clinical significance in
oral cancer remains ill defined. In this work, we investi-
gated the role of PAK1 in oral cancer. Our study sug-
gests that PAK1 plays a crucial role in the progression of
oral cancer and represents a potential therapeutic target
in OSCC.
Results and Discussion
OSCC cell lines showed differential expression and
localization patterns for PAK1
Very few studies have elucidated the expression pattern
of PAK1 in OSCC cell lines. We analysed the expression
and localization patterns of PAK1 in the five OSCC cell
lines. Our study demonstrated that all the five OSCC cell
lines differentially expressed PAK1 (Fig. 1a).
Localization pattern of proteins play a key role in can-
cer. Previous studies have shown that PAK1 localizes in
the cytoplasm, nucleus or to the cell membrane. An
earlier study had demonstrated that PAK1 expression in
breast tumors positively correlated with tumor grade,
with higher expression in grade 3 [40]. Another study in-
volving an established murine model of breast cancer
progression had shown that PAK1 expression and its nu-
clear localization were progressively increased during
the transition from ductal hyperplasia to ductal carcin-
oma in situ to adenocarcinoma [41]. Holm et al. [42]
had suggested that PAK1 activation and its nuclear
localization may be one of the mechanisms responsible
for reduced tamoxifen sensitivity of breast tumor cells.
Even though there are studies in other cancer types that
Fig. 1 Expression and localization patterns of PAK1 in the five OSCC
cell lines. a OSCC cell lines (SAS, HSC4, RCB1015, RCB1017 and
RCB1034) used in our study showed differential expression levels of
PAK1. b PAK1 exhibited differential localization patterns in OSCC cell
lines. PAK1 predominantly localized in the nucleus in HSC4 cells,
whereas in SAS and RCB1015, PAK1 showed a predominant
cytoplasmic localization. While in RCB1017, PAK1 was found in both
nuclear and cytoplasmic compartments, in RCB1034, PAK1 was
mostly showing nuclear localization pattern
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correlated the localization patterns and cancer progres-
sion, this issue has not been investigated in oral cancer
as yet.
To study the localization patterns of PAK1 in OSCC
cell lines, confocal microscopy was performed in OSCC
cell lines which were exponentially growing in 10 %
Foetal Bovine Serum containing medium. The results of
confocal microscopy revealed that PAK1 predominantly
localizes in the nucleus of HSC4 cells and RCB1034
cells, while in SAS cells and RCB1015, PAK1 was pre-
dominantly in the cytoplasm (Fig. 1b). In the case of
RCB1017, PAK1 was observed in both the nuclear and
cytoplasmic compartments.
Differential localization of PAK1 and cytoskeleton
remodelling in serum-stimulated OSCC cells
Growth factors and their receptors play a very crucial
role in cancer progression. Previous reports suggested
that over-expression of Epidermal Growth Factor Recep-
tor (EGFR) [43] and Transforming Growth Factor β1
(TGF β1) [44] are associated with increased malignant
potential and correlated with poor treatment outcome
in head and neck cancer. Growth factors are known
to recruit PAKs to the membranes, where they come
in contact with other activating kinases, leading to
the downstream signalling cascade.
To study the effect of serum growth factors on the
localization of PAK1, HSC4 cells were grown in serum
free condition. After 48 h, cells were cultured in the
presence of medium containing 10 % serum for varying
time intervals and the localization patterns of PAK1
were studied. It was observed that in serum-free condi-
tion, PAK1 predominantly resides in the nucleus, but
upon stimulation with serum, PAK1 largely accumulates
in the cytoplasm (Fig. 2a). This suggests that PAK1
localization is regulated by the growth factors and
in-turn, differential sub-cellular PAK1 localization
may influence its ability to trigger cytoskeleton remodel-
ling in the cytoplasm.
To analyse the effect of growth factors on actin re-
modelling in OSCC, HSC4 cells were grown in serum
free condition. After 48 h, cells were cultured in medium
containing 10 % serum for varied time intervals and
Phalloidin staining was done after fixing the cells. As
shown in Fig. 2b, actin was mostly in the condensed
form and was concentrated mostly in the periphery of
the cells grown in serum-free conditions. However, a
more prominent actin network was visible in serum-
stimulated cells. These observations suggest that PAK1
predominantly localizes in the nucleus in serum-starved
OSCC cells with a condensed actin network. However,
PAK1 translocates to the cytoplasm in serum-stimulated
cells wherein it might participate in actin remodelling.
Further experiments would provide conclusive evidence
regarding the suggested role of PAK1 in regulating the
cytoskeletal structures of OSCC cells.
Potential role of PAK1 in the cytoskeletal remodelling,
invasiveness and motility of OSCC cells
Cytoskeletal remodelling plays an essential role in the
cell motility. For a productive cancer progression, the
malignant cells must undergo dynamic changes in
Fig. 2 Effect of serum growth factors on PAK1 localization and its potential role in regulating actin cytoskeletal structures. HSC4 cells were serum
starved for 48 h and treated with or without medium containing 10 % FBS for varying intervals of time. One set of plates were subjected to
localization studies (a) while the second set was stained with Phalloidin 488 (b)
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cytoskeletal structure, thereby enabling the cancer cells
to migrate and invade the neighbouring tissues. As men-
tioned earlier, PAK1 has been implicated in the progres-
sion of different cancer types. However, its role in oral
cancer remains poorly studied. To study the effect of
PAK1 in the cytoskeletal remodelling, motility and inva-
siveness of OSCC cells, PAK1 was selectively knocked
down in the SAS cells (Fig. 3a) and such cells were sub-
jected to Phalloidin staining, wound healing assay and
Matrigel invasion assay. Phalloidin staining of control
and PAK1 kock-down SAS cells (Fig. 3b) demonstrated
that the actin structures and the morphology of the cells
were intact in the control cells with PAK1, while these
structures were profoundly reorganized in OSCC cells
with depleted PAK1, indicating that PAK1 might be es-
sential for cytoskeletal remodelling of OSCC cells. Fur-
ther experiments are required to establish the role of
PAK1 in cytoskeletal remodelling of OSCC cells.
To study the motility of OSCC cells with or without
PAK1 knock-down, we next performed Wound healing
assay. It was observed that even after 24 h of growing
the cells with PAK1 knock-down in serum containing
medium, the wound was not completely healed (Fig. 3c)
as compared to the control cells with almost a complete
wound healing. To exclude a potential influence of ex-
pected proliferation difference in 10 % FBS-containing
medium, a set of cells were also grown in growth factor-
free medium. This observation suggested that PAK1 may
be involved in the motility of growth-factor stimulated
OSCC cells.
Another pre-requisite for cancer progression is the
ability of cancer cells to invade into the neighbouring
normal tissue, thereby facilitating the process of metas-
tasis. To study the involvement of PAK1 in this process,
we subjected OSCC cells with or without PAK1 knock-
down to Matrigel invasion assay. It was observed that
when compared to the control cells, cells with PAK1
knock-down showed almost four fold decrease in the in-
vasiveness, suggesting that PAK1 is also involved in the
invasiveness of OSCC cells (Fig. 3d).
Additionally, we had done an in-silico analysis to
survey PAK1 phosphorylation sites in differentially
expressed genes in OSCC by using the software GPS
(Group-based prediction system) 2.1 [45]. Out of the
64 genes that are differentially expressed in OSCC,
26 genes (Additional file 1) were found to have PAK1
phosphorylation sites. Further functional studies are re-
quired to confirm this in-silico finding.
Conclusions
We had ventured into an under-investigated area in can-
cer biology i.e., the role of PAK1 in the progression of
OSCC. PAK1 was found to be differentially expressed
and localized in OSCC cell lines used for our study.
Because growth factors are potent inducers of PAK1
activation, we studied the response of OSCC cells by
Fig. 3 Biological effects of PAK1 knock-down in OSCC cells. a Immunoblot analysis of PAK1 expression in control and PAK1 knock-down SAS cells
and its densitometric quantitation. b Phalloidin staining showing actin structures in the SAS cells treated with the control or PAK1 siRNA. c Wound
healing assay in the SAS cells treated with the control or PAK1 siRNAs. d Fluorescent images obtained after matrigel invasion assay, showing the
cells (stained with Dil C) that have migrated through the matrigel. A quantitative representation of the image data is also illustrated
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serum growth factors. It was observed that serum growth
factors facilitate the translocation and/or accumulation of
PAK1 in distinct sub-cellular compartments, and also, it
might affect the cytoskeletal structures of OSCC cells.
Migration and invasion of cancer cells are under the con-
trol of dynamic cytoskeletal re-organization, in addition to
other pathways. We found that PAK1 plays a potential
role in cytoskeletal remodelling of OSCC cells, thereby
affecting the motility and invasiveness of OSCC cells.
Further studies are required to bring out the mechanistic
insights into the role of PAK1 in oral cancer progression.
In brief, PAK1 plays a crucial role in OSCC progression
and that studying the role of PAK1 could improve our un-
derstanding of oral carcinogenesis and in determining
new therapeutic targets for oral cancer.
Methods
Cell culture
Oral cancer cell lines like SAS, HSC4, RCB 1015, RCB1017
and RCB1034 were used for the study. Out of this, SAS
and HSC4 are human tongue squamous cell carcinoma cell
line whereas RCB1015, RCB1017 and RCB1034 are OSCC
cell line obtained from the same patient in different stages
of tumor progression. RCB1015 is a G-CSF producing
OSCC cell line, RCB1017 is a G-CSF and IL-1 produ-
cing oral squamous cell carcinoma whereas, RCB1034 is
a human cell line derived from metastasis of cancer oc-
curred in oral cavity. All the cell lines were obtained from
Riken BRC (BioResource Center) Cell bank, Japan. The
cells were grown in Dulbecco’s modified Eagles medium
(DMEM) (Sigma-Aldrich, St. Louis, MO) and RPMI 1640
medium (developed at Roswell Park Memorial Institute)
supplemented with 10 % heat-inactivated fetal bovine
serum (FBS; Invitrogen), and antibiotic and anti-mycotic
cocktail (Lonza).
Immunoblot analysis
Immunoblot analysis was done as mentioned in Haneef
et al. [46]. Briefly, cells were washed with PBS and lysed
using RIPA (Radioimmunoprecipitation assay) buffer
(150 mM NaCl, 1 % NP-40, 0.5 % Sodium deoxycholate,
0.1 % SDS, 50 mM Tris–HCl pH 7.4) containing prote-
ase inhibitor cocktail (Sigma-Aldrich Inc., USA). Briefly,
equal amount of protein as determined by Bradford
assay was subjected to SDS-PAGE, followed by transfer
to nitrocellulose membrane (Millipore, MA). The mem-
brane was then blocked in 5 % powdered non-fat milk
Tris solution for 1 h. Membrane was then incubated
overnight with primary antibody, followed by incubation
with species-specific horseradish peroxidase (HRP) con-
jugated secondary antibody (1:5000, Santa Cruz) at room
temperature for 1 h. Protein bands were visualised on X-
ray film using ECL-plus reagents (Amersham, NJ). The
primary antibodies were: PAK1 (1:5000, Bethyl Labs) and
Beta actin (1:5000, Sigma).
Confocal immunofluorescent microscopy and phalloidin
staining
The oral cell lines (SAS, HSC4, RCB1015, RCB1017 and
RCB1034) were cultured on glass coverslips until 60–
70 % confluence. Cells were fixed in chilled 4 % parafor-
maldehyde solution in PBS at 4 °C for 7 min and then
permeabilized with 0.1 % Triton X 100 for 7 min at
room temperature, followed by three washes using PBS.
Non-specific protein binding was reduced by incubation
in 3 % BSA at room temperature for 1 h. The cells were
then incubated with primary antibodies for PAK1 (dilu-
tion: 1:500) at 4 °C for overnight. The cells were washed
twice with PBS, followed by incubation with secondary
antibody conjugate for 1 h at room temperature and nu-
clear staining was done using Hoechst staining (5 μg/ml)
for 5 min. For Phalloidin staining, the cells were treated
with Alexa Fluor® 488 Phalloidin (dilution: 5 μM) for
20 min. After giving a wash with PBS twice, the cells
were stained with the nuclear dye Hoechst 33342
(Invitrogen, 5 μg/ml). Again, the cells were washed
twice in PBS. The coverslips were mounted in Glycerol on
glass slides and sealed with nail polish. Microscopic
observations were made using laser scanning confocal
microscope (Nikon A1R). Localization pattern of PAK1
was studied using Immunofluorescent detection of the
protein while F-Actin structure was studied using Phal-
loidin staining.
siRNA transfection
SAS cells were seeded on 6 well plates and incubated for
48 h in complete medium. The cells were transfected
with 100nM of siRNA specific for human PAK1
(pSUPER PAK1 siRNA) or control siRNA (sc-37007,
Santacruz) using the Lipofectamine LTX and PLUS
siRNA transfection reagents as per the manufacturer’s
instruction. 12 h after transfection, transfection
medium was replaced with fresh medium containing
serum and allowed to grow for 24 h. Whole cell ex-
tract was prepared 36 h after transfection for analysis
of silencing efficiency by western blot using antibody
against PAK1 (Bethyl Labs, A301-259A).
Matrigel invasion assay
The cell invasion assay was conducted using BioCoat
Matrigel (Becton Dickinson Biosciences) by following
the manufacturer’s protocol. After transfection with
either anti-PAK1 or control siRNAs, cells were seeded
into the upper chamber at a density of 1 × 105 cells per
well in 0.2 ml of 1 % FBS medium. The lower chamber
contained complete culture medium, which included
10 % FBS to attract invading cells. Cells were incubated
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at 37 °C for 24 h, and the number of cells that invaded
through the Matrigel-coated membranes was counted
and compared with the number of cells that passed
through the membrane in the control chambers. The in-
vaded cells on lower side of membrane were fixed,
stained with Dil C stain, and photographed.
Wound healing assay
Cell migration was evaluated by an in vitro wound-
healing assay. After transfection with either anti-PAK1
or scramble siRNAs, 5 × 105 cell/ml transfectants was
seeded in a 24 well plate. After the culture had formed a
monolayer, a cell-free gap was produced with the help of
a yellow tip. After changing to culture medium with 1 %
FBS, the cell migration status toward the gap area was
photographed after 24 h.
Additional file
Additional file 1: The FASTA sequences of differentially expressed
genes were examined using GPS2.1 software to analyse the presence of
PAK1 phosphorylation sites. Using highly stringent condition, we recognized
26 genes with putative PAK1 phosphorylation sites. (XLSX 10 kb)
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